Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth bags bifeprunox

Executive Summary

Six months after receiving a "not approvable" letter for the atypical antipsychotic bifeprunox, Wyeth announces Feb. 29 it is backing out of a development and commercialization deal for the schizophrenia drug with Solvay Pharmaceuticals. "We met with FDA, and while they did talk about there being a path forward [for bifeprunox], Wyeth conducted an assessment, and at the end of the day, decided there wouldn't be enough commercial value for both companies to share," the firm tells "The Pink Sheet." Wyeth initially said it likely would pursue development of bifeprunox for the maintenance of stable adult patients with schizophrenia but would not pursue an acute treatment indication after receiving the not approvable letter in August (1"The Pink Sheet," Aug. 13, 2007, In Brief)
Advertisement

Related Content

Wyeth’s bifeprunox “not approvable”
Advertisement
UsernamePublicRestriction

Register

PS049372

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel